For frontline treatment of CD30-expressing PTCL, BV in combination with cyclophosphamide, doxorubicin, and prednisone is approved in the US, Europe, and other parts of the world for treatment of patients with sALCL or more broadly in the US for treatment of patients with CD30-expressing PTCL. Here, TNFRSF8 is linked to mature T-cell and NK-cell non-Hodgkin lymphoma.